• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
162563 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

  j4 z# P. w3 t; S' {& ]% X可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
: f# i" {- O6 {5 m; I1 s- a; n$ m
% R; }7 x7 R+ c" h
. c  s- O! s( F. f9 N$ h' bSub-category:3 J6 R; e. m1 `8 _' [' d; v! X* v( u- X
Molecular Targets - x* Z; n/ u$ y+ T# B

- h& S& `, l! j4 |# Z7 S* K+ o# O8 G% l' O/ Q, z7 P
Category:/ V9 l- F" _7 Z( ]0 m0 E, J. O$ F6 ^$ S: X
Tumor Biology + k4 h- j6 j* V6 g

3 k( {: P! h/ X5 N2 x% B3 `+ \! Z% A6 U
Meeting:
: U* M. e4 U+ h' L9 _2011 ASCO Annual Meeting # |* F* X+ ?) m

/ ^/ w  `- V7 n/ g2 c* D' [( s' o( n: |2 [. ~, k) s+ N
Session Type and Session Title:
3 D# q" y$ ]. v7 }; r$ f, nPoster Discussion Session, Tumor Biology
& f% Y" K1 ]- Q6 ?' O1 K) P8 W" Y- C' B/ L$ y% G: I9 \4 o

9 q: U5 D6 C% \7 g8 g( n% WAbstract No:
3 M  A; n2 j& W) E& Y10517
0 w' k+ Q- D7 Q, a' S+ X7 p! {1 `5 p4 Z1 E) m. c4 }

% i1 t9 K& _' k' E% gCitation:0 V# f3 k3 Z* ?: ~  d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
# P: J! _8 j" G" S2 ^' g. P: D( V) T3 F' [+ g9 P) ~* X' L
( J3 F) s+ ?* w' |; R2 c0 W
Author(s):- u: O' P8 z% f) ]( d* f
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China " |/ b$ C# L, I- ?

' \; T' z( q1 @! d$ f) Q
7 t* [* j3 E) J; v4 Y) C# g; X5 E* B% |, d0 G% b. X
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
& E' ^' g% P/ H5 V  z
$ A% ]. A8 k& zAbstract Disclosures4 Z" V! R; f, h+ m( P
$ ?$ x6 X- u0 B7 c, f
Abstract:0 a; C+ J2 u" a2 s2 n

8 p5 x7 S  d! x4 O: C& |+ m- O7 u! ^- {  E
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
+ V. D2 k7 T' d& @+ b8 L0 b( l. s% Z0 q3 M( l; [, Y

& D* n( y6 s6 u/ u- C. q
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 : t8 |. j. G2 }2 G  T$ ]3 p
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
# Q4 W8 z  b  C" @: i. X* n
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
2 Z3 {% y$ m* k1 H易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。1 s3 {+ B0 V% Z+ `7 b( S
ALK一个指标医院要900多 ...

, V* [- o/ M& i4 c. C& u) e2 V" t) A平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?4 N- j& K, A1 U. E# w* }
+ Y/ E4 b9 U# B- {" o& H; N) V
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表